GREG SIMON was named executive director of the national moonshot cancer initiative by Vice President Joe Biden. Previously, he helped start the charity FasterCures in 2003. In 2009, he became senior vice president for patient engagement at Pfizer. Most recently, he was chief executive of Poliwogg, a financial services company. Simon was diagnosed with leukemia...
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
